Virtual Library

Start Your Search

Nan Bi



Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-65 - First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs (ID 12140)

      12:00 - 13:30  |  Author(s): Nan Bi

      • Abstract
      • Slides

      Background

      Tyrosine kinase inhibitors (TKIs) have been widely accepted as first-line therapy for patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC), achieving a median progression free survival (PFS) and overall survival (OS) of 8.0 to 13.1 months and 19.3 to 30.9 months respectively. Patterns-of-failure studies suggest that the first progression after first-line TKIs occurs most often at sites of disease known to exist at the baseline. In this retrospective study, we aimed to investigate whether the radical local therapy could offer survival benefit in addition to st

      a9ded1e5ce5d75814730bb4caaf49419 Method

      NSCLC patients with activating EGFR mutations and treated with TKIs as first-line management after the diagnosis of stage IV disease (either synchronous or metachronous) between 2010 and 2017 at our institution were reviewed. All enrolled patients should receive radical local therapy (either surgery or radiotherapy with curative intent) at least to the main site of disease. We defined the main site as the primary site for synchronous IV-stage patients and at least 1 progression site for metachronous IV-stage patients. OS and PFS were calculated from the first day of IV-stage treatment. Kaplan-Meier method was used for survival estimation and Log-rank test was rendered for survival comparison between groups.

      4c3880bb027f159e801041b1021e88e8 Result

      A total of 45 patients entered into the final analysis, including 18with synchronous stage IV diseases and 27patients with metachronous diseases. A total of 208 gross tumor sites were identified and 130 of them received local treatment, including 90 sites treated with radical approaches and another 30 sites with palliative therapy. At a median follow-up period of 37.8months, the median OS was 51.4 months, with 1-, 3- and 5-year rate of 97.7%, 58.7% and 25.2%, respectively. The median PFS was 16.4months, with 1-, 2- and 3-year rate of 64.7%, 29.1% and 6.8%, respectively. There was no difference between synchronous and metachronous groups. In 38patients who progressed, 19 (42.2%) involved new metastatic sites only, 12(26.6%) involved initial sites only, and 3 (6.7%) involved both.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Metastatic EGFR-mutant NSCLC patients who received TKIs and radical local therapy in our study obviously provided longer OS and PFS compared with historical results using TKIs alone. Prospective randomized evidences are warranted to clarify the clinical efficacy of additional local therapy to first-line TKIs for this highly selective subgroup of patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.